Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13506359 | 1.00 | MAPT (0.50) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3424276 | 1.00 | MAPT (0.50) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12491318 | 0.84 | MAPT (0.37) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL333798 | 0.84 | MAPT (0.37) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27799879 | 0.84 | MAPT (0.47) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL28062436 | 0.84 | MAPT (0.47) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL12292882 | 0.84 | MAPT (0.47) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| Toluene SCHEMBL3090911 | 0.84 | MAPT (0.39) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL24838495 | 0.81 | MAPT (0.45) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27559880 | 0.81 | CHRNB2 (0.33) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4462999-A1 | PROTOPORPHYRINOGEN OXIDASE INHIBITORS | Enko Chem, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4385991-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| US-20240166649-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI VISONPHARMA CO., LTD. (CN) | 2024-05-23 | — | — | US | disclosed |
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| CN-117881678-A | Compound with SHP2 protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | AXIAL THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-117645614-A | Substituted heterocyclo-cyclic compounds, preparation and pharmaceutical use thereof | 劲方医药科技(上海)有限公司 | 2024-03-05 | — | — | CN | disclosed |
| EP-4293022-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Visonpharma Co., Ltd. (CN) | 2023-12-20 | — | — | EP | disclosed |
| WO-2013110890-A1 | NEW INDOLIZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2013-08-01 | — | — | WO | disclosed |
| US-20130090340-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-04-11 | — | — | US | disclosed |
| CN-102421779-A | Dihydropteridinone derivatives, preparation method and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO | 2012-04-18 | — | — | CN | disclosed |
| EP-1928886-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SmithKline Beecham Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| CN-1694703-A | Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-09 | — | — | CN | disclosed |
| WO-2005079799-A1 | 4-ACYL-PIPERAZINES AS ANTI-VIRAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| EP-1144368-B1 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090340-A1 | 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCN1, HCN2 | MAPT 4298/4885GRIN2D 3470/4885GRIN3B 2419/4885 |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | MAPT 1533/4885GRIN2D 3812/4885GRIN3B 2569/4885 |
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | MAPT 4192/4885GRIN2D 891/4885GRIN3B 461/4885 |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | TLR2, TLR3, TLR4 | MAPT 4192/4885GRIN2D 891/4885GRIN3B 461/4885 |
| US-20240166649-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | DPYD, GOT1, WEE1 | MAPT 3938/4885GRIN2D 3516/4885GRIN3B 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.